- Home
- KALV vs VTS Comparison
KALV vs VTS Comparison
Compare KALV & VTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- VTS
- Stock Information
- Founded
- KALV N/A
- VTS 2014
- Country
- KALV United States
- VTS United States
- Employees
- KALV N/A
- VTS N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- VTS Oil & Gas Production
- Sector
- KALV Health Care
- VTS Energy
- Exchange
- KALV Nasdaq
- VTS Nasdaq
- Market Cap
- KALV 796.4M
- VTS 895.8M
- IPO Year
- KALV N/A
- VTS N/A
- Fundamental
- Price
- KALV $10.95
- VTS $23.52
- Analyst Decision
- KALV Strong Buy
- VTS Strong Buy
- Analyst Count
- KALV 8
- VTS 4
- Target Price
- KALV $26.43
- VTS $28.25
- AVG Volume (30 Days)
- KALV 1.5M
- VTS 362.4K
- Earning Date
- KALV 09-11-2025
- VTS 11-03-2025
- Dividend Yield
- KALV N/A
- VTS 9.57%
- EPS Growth
- KALV N/A
- VTS 27.28
- EPS
- KALV N/A
- VTS 1.12
- Revenue
- KALV $1,426,000.00
- VTS $239,904,000.00
- Revenue This Year
- KALV N/A
- VTS $28.41
- Revenue Next Year
- KALV $213.43
- VTS N/A
- P/E Ratio
- KALV N/A
- VTS $21.06
- Revenue Growth
- KALV N/A
- VTS 4.55
- 52 Week Low
- KALV $7.30
- VTS $18.90
- 52 Week High
- KALV $17.28
- VTS $28.41
- Technical
- Relative Strength Index (RSI)
- KALV 27.85
- VTS 41.62
- Support Level
- KALV $11.93
- VTS $22.93
- Resistance Level
- KALV $12.43
- VTS $24.56
- Average True Range (ATR)
- KALV 0.60
- VTS 0.58
- MACD
- KALV -0.22
- VTS -0.06
- Stochastic Oscillator
- KALV 6.17
- VTS 33.64
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About VTS Vitesse Energy Inc.
Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.